Opaleye Management »

Precigen shares owned by Opaleye Management

Quarter-by-quarter ownership of Precigen (PGEN) shares owned by Opaleye Management from 13F filings

Historical chart of Opaleye Management investment in Precigen

Tip: Access up to 7 years of quarterly data

All positions including Precigen held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Precigen by Opaleye Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.4M 1.0M 1.34
2023-09-30 $1.3M 929k 1.42

More positions owned by Opaleye Management

Harrow Health (HROW)
Tg Therapeutics (TGTX)
Acelyrin (SLRN)
Rhythm Pharmaceuticals (RYTM)
Ocular Therapeutix (OCUL)
Catalyst Pharmaceutical Partners (CPRX)
Keros Therapeutics (KROS)
Ideaya Biosciences (IDYA)
Eton Pharmaceuticals (ETON)
Crinetics Pharmaceuticals In (CRNX)
Arvinas Ord (ARVN)
Codexis (CDXS)
Biohaven (BHVN)
Edgewise Therapeutics (EWTX)
Iovance Biotherapeutics (IOVA)

View all positions for Opaleye Management

Top funds holding Precigen

Patient Capital Management
Vanguard Group
Millennium Management
Iridian Asset Management
Jpmorgan Chase & Co
Opaleye Management
D. E. Shaw & Co
Charles Schwab Investment Management
Sanders Morris Harris
GSA Capital Partners
Citadel Advisors
Emfo
Bank of New York Mellon
Jacobs Levy Equity Management
Bank of America Corporation

View all funds holding Precigen